poisar

Stocks · News reference

Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

Benzinga Newsdesk

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VKTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Lee Samaha

    4 High-Risk Stocks Built for Big Returns

    The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

    AGIONVTSJOBYVKTXLLY
  3. Lee Samaha

    Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

    Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030.

    VKTXLLY